511 related articles for article (PubMed ID: 24007408)
1. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
Rothstein RD; Friedenberg FK
Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
[TBL] [Abstract][Full Text] [Related]
2. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
Vazquez-Roque MI; Bouras EP
Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
5. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
Lee N; Wald A
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
[TBL] [Abstract][Full Text] [Related]
8. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
[TBL] [Abstract][Full Text] [Related]
9. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock EJ; Cheng V; Cremonini F
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
[TBL] [Abstract][Full Text] [Related]
10. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
12. New treatment targets for the management of irritable bowel syndrome.
Rao S; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
[TBL] [Abstract][Full Text] [Related]
13. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
Layer P; Stanghellini V
Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
Rey E; Mearin F; Alcedo J; Ciriza C; Delgado-Aros S; Freitas T; Mascarenhas M; MÃnguez M; Santos J; Serra J
Adv Ther; 2017 Mar; 34(3):587-598. PubMed ID: 28083815
[TBL] [Abstract][Full Text] [Related]
15. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
Love BL; Johnson A; Smith LS
Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
[TBL] [Abstract][Full Text] [Related]
16. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Vazquez Roque M; Camilleri M
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
[TBL] [Abstract][Full Text] [Related]
17. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
McCormack PL
Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological and clinical profile of linaclotide (Linzess
Keto Y; Kosako M
Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535
[TBL] [Abstract][Full Text] [Related]
20. New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S; Miner PB
Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
